
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis
December 2nd 2025Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.